Matthew T. Roe

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

Gregory G. Schwartz, Philippe Gabríel Steg, Michael Szarek et al. · New England Journal of Medicine · 2018 · 3.5K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

Vera Bittner, Michael Szarek, Philip E. Aylward et al. · Journal of the American College of Cardiology · 2020 · 572 citations · Full text

Medicine, Cardiology, Pharmacology +17

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial

Gregory G. Schwartz, Laurence Bessac, Lisa G. Berdan et al. · American Heart Journal · 2014 · 411 citations · Full text

Medicine, Cardiology, Pharmacology +17

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study

Herbert D. Aronow, Eric J. Topol, Matthew T. Roe et al. · The Lancet · 2001 · 315 citations

Medicine, Cardiology, Pharmacotherapy +15